this pharmeceutical is diverging bullishly daily stochwere up 15% AH and trying to consolidate if we can hold the $0.49 area and stay out of oversold stoch on the daily beating $0.545 and breaking $0.668 level stock should revisit the $0.71-$0.78 area predicting rangebound price action
PHARMA
Cipla BreakoutThe stock has broken out and retested, therefore may undergo a reversal rally. Trade is supported by Supports Nearby.
Risk Reward Ratio - 2:1
SL is placed below the support zone & the lower trendline. The target is placed near resistance.
ATER PharmaATER has traded down to a support level and 0.62 Fib retracement. ATER has an upcoming pharmaceutical approval from the FDA for one of their drugs which remains in stage 2 trials.
INNO Trades Steady, Outperforms the CSE25 and HMMJ Marijuana ETF$INNO.CN stock grew by +3.39% on Friday, stock opened at $0.590 and closed at $0.610, meanwhile price action is working above 20 EMA in daily chart that shows stock is bullish in nature and MACD is also showing strength in stock. RSI is close to par, indicating that current share price is fairly valued. The market cap of the company is 159.073M, and its average 3mo volume is 52k. Last week amidst pronounced downturns in major markets and indexes, INNO continued to trade steadily, and outperformed the CSE25 Composite Index alongside the TSX's HMMJ Marijuana ETF. Despite serious background volatility, the legalization of recreational cannabis use in New Jersey and its steadily progressing R&D pipeline are clear bullish indicators for INNO's LT potential
PFE: Sell Zone is 58-60Pfizer's W-4 bottomed right in our "Buy Zone" and has bounced 10% since. I expect Pfizer to continue to climb up to the $58-60 level over the coming 2 weeks or so. After that, Pfizer will pull back for it's larger degree W-2, which should bring price back to about the $50 level. We will have more clarity on pullback targets once W-5 tops, most likely in our "selling zone". The point is, this is not an idea time to start a position. I will be selling covered calls against my shares of Pfizer when we reach the selling zone, and will be looking to add shares for about $50 sometime in Late May/Early June.
Mid-cap Pharma Company might get a booster dose.Mid-cap Pharma Company might get a booster dose?
The 31,177.59 Cr. worth mid-cap Pharma company, Laurus Labs Ltd. gave a massive 96% CAGR (3yrs.) in the past. The share price of the company made a high of Rs. 723.55 after which it saw a downturn is now giving signals of its trend reversal to Bullish. The share price of the company made an 'inverted Head and Shoulders' pattern which is a bullish trend reversal pattern. Also, the share price might also see a 50 & 100 EMA crossover in the next 1-3 trading session which again makes it a positive for traders & investors. In clear words, the target for the share is 665 - 685, with a mid-term view of 2- 12 weeks. The stock might retest the level of 550 - 560 (precisely Rs. 555) which would also make it the ultimate support.
Also, please consult your financial advisor before entering into any trade. This piece of knowledge is shared only for educational purposes. Thank You & keep learning!
ARDS upside potentialARDS Aridis Pharmaceuticals has 2 Phase 3 Clinical Trials for 2022, one Phase 2a study, a fully human monoclonal antibody (mAb) cocktail against COVID and a funding from the Gates Foundation to support development of inhaled formulation technology to deliver cost-effective monoclonal antibodies against influenza and COVID-19.
And the Market Cap is only 23.892Mil.
In my opinion this stock can double in trice anytime, their pipeline is highly undervalued.
NRXP all time low! 2 X Phase 3 clinical trials! NRx Pharmaceuticals, Inc. (NRXP) has two Phase III assets for which it has Fast Track and Breakthrough Therapy designation, respectively: intravenous ZYESAMI® for Critical COVID-19 and NRX-101 for bipolar depression with suicidality.
52 Week Range 2.38 - 48.80.
in 2020 the stock was $77.
My price target is 16.50
If this is not the time to buy this stock, then when?!
PALI +500% potential according to this analystPalisade Bio, Inc. (PALI) plans to initiate a phase 3 study for accelerating the return of bowel function in the first half of 2022 and for the first patient to be enrolled in the second half of 2022.
On 2/2/2022 LADENBURG THALM/SH SH brokerage Initiated Coverage for PALI with a Buy rating and $5.00 Price Target.
Market Cap 12.841Mil
52 Week Range 0.76 - 16.02
I think this stock can easily double in price this year.
Buy WockPharma above 408 SL 389 TGT 487Wock Pharma at very strong support . i used 4 hour time frame to analysis the above stock . entry and exit are based on P &F charts 1% box reversal method . why i choose the point and figure is the method give you exact price to enter and exit . please use stop loss .
"Long BIOCON above 380 "Falling trendline breakout with increasing volume
Biocon looking bullish if it close above 380 ,wait for closing ,
looks good for target of 420,480
NVNOTook a little nibble on NVNO. Chat doesnt look to bad with price at the bottom of the range and making a nice W. The book also look pretty clean with a low share count finviz.com
Excellent opportunity in DivislabDIVISLAB have taken support and forming pole and flag . Going to break channel and start up move. Targets are mentioned, must comment if have any suggestion. NSE:DIVISLAB
Buying Moderna HereBuying Moderna here, may be printing a double bottom on weekly. They arent going to let this pandemic go away so banking on more vaccines and more fun for a few more years at least. It is still WAY up from a few years ago so setting tight stops. Not advise.
CWBR Upside PotentialCWBR closed 2 months ago a $15.0 Million Public Offering of Common Stock and Warrants at $0.72, so this is a safe upside in my opinion if you want to enter now.
On the other hand, Cantor Fitzgerald brokerage has a $2.5 price target for it.
52 Week Range 0.34 - 2.27 Just bounced from its lowest support.
GSK Breakout RetestThe stock has broken out and retested, therefore may undergo a reversal rally. Trade is supported by brokerage calls and Supports Nearby.
Risk Reward Ratio - 2.5:1
SL is placed below support zone & the lower trendline. The target is placed near resistance.
ACRX Daily Long Double Bottom Bullish Long TermACRX has reached the lowest price @.46 a share, it has also double bottomed on the daily, the daily candle is bullish .. Looking to ride this buy for a long term.
Going to ride it up to the red resistance trendline, if it becomes support it should reach $2 to $4. Happy New Year..
ARDS Covid-19 First-in-Class Antibody | +818% Analyst Rating ! Analyst Vernon Bernardino from H.C. Wainwright, who reiterated a buy rating and $19 price target on ARDS, told investors Wednesday that Aridis Pharmaceuticals Inc 's monoclonal Covid-19 Antibody Cocktail is potentially First-in-Class treatment: "the cocktail binds to the S2 spike protein subunit, which mediates viral cell membrane fusion in SARS-CoV-2 variants and also binds to the omicron variant with no loss in affinity compared to the original Wuhan strain."
Cantor Fitzgerald also said last week that Aridis' pipeline is "underappreciated."
ARDS Pan-Coronavirus Monoclonal Antibody Cocktail Retains Effectiveness Against the Omicron variant, other COVID-19 Variants, SARS, MERS, and the Common Cold Human Coronaviruses.
It provides relevant drug levels for up to 1 year from prophylactic or therapeutic treatment.
Market Cap of only 32.605Mil
52 Week Range 1.89 - 8.47
I think this might be our 10X stock for 2022.
Happy New Year!
QNRX Market Outperform Price Target !!Yesterday, JMP Securities Initiated Coverage on Quoin Pharmaceuticals, Ltd. (QNRX) with a Market Outperform rating and a price target of 8usd.
Quoin Pharmaceuticals (NASDAQ: QNRX) is positioned to deliver the first FDA-approved treatment for Netherton Syndrome, a devastating disorder which affects 1 in every 200,000 people worldwide.
This month, QNRX Signed Multiple Exclusive Distribution Agreements for in various regions of the globe for its Lead Asset, QRX003, for Netherton Syndrome.
My price target is the 12usd resistance.
Cipla at a crucial point at 200 DEMACipla weekly chart shows price is at a crucial point just standing on the 200DEMA line.
Stock has been in the range of 873-1006, which currently is at the bottom of the range.
Crucial to hold 200DEMA to move up, if breakdown then may move towards the lower range marked in the chart.
*Only for educational purposes, not a buy/sell recommendation.
AbbVie: Breakout! Buying a re-test of supportAbbVie - Short Term - We look to Buy at 119.00 (stop at 114.50)
Previous resistance level of 119.95 broken. A move higher has resulted in prices breaking from the previous range and confirmed our bullish expectation. We have a Gap open at 118.86 from 03/12/2021 to 06/12/2021. Further upside is expected although we prefer to set longs at our bespoke support levels at 119.00, resulting in improved risk/reward.
Our profit targets will be 135.00 and 150.00
Resistance: 122.42 / 124.00 / 130.00
Support: 119.95 / 118.86 / 115.03
Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis, like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis, as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features.
Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
FENC Analysis - Dip Buy0.786 can be seen as a previous point of resistance
now that price has moved higher than this level, it will be seen as a point of support for the breakdown of the rising wedge , a pattern that is commonly bearish (as you can see on the chart)
Pharmaceutical companies are possibly hot right now, due to the emergence of the new COVID variant.
Buy the Dip.
